In addition to our internal endocrinology rare disease and oncology pipelines, we have collaborations with biopharmaceutical companies leveraging the TransCon technology platform to develop products in other therapeutic areas.
Ascendis Pharma currently has strategic product development collaborations with:
Our collaboration partner, Roche Genentech, is applying TransCon technology to develop TransCon prodrug candidates for the treatment of age-related macular degeneration (AMD) and other ophthalmology indications.
Our collaboration partner, Sanofi, is developing long-acting TransCon peptide prodrugs for the treatment of diabetes.
TransCon Technology Platform
Learn how we’re using our innovative TransCon technology (abbreviated from “transient conjugation”) to create potential best-in-class products to address unmet patient needs in endocrinology rare diseases.